Change of Adviser

About this update from Ekf Diagnostics Holdings Plc

EKF Diagnostics Holdings plc ("EKF", the "Company" or the "Group")   Change of Adviser   EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , announces Singer Capital Markets as sole broker to the Company. Singer Capital Markets also continues to act as Nominated Adviser.     EKF Diagnostics Holdings plc www.ekfdiagnostics.com Mike Salter, CEO / Marc Davies, CFO  Tel: +44 (0)29 2071 0570 Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / George Tzimas / Oliver Platts Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303     About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:   Point-of-Care Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.   Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor , Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin   Life Sciences Enzyme fermentation, Custom products and Bulk fermentation   Contract Manufacturing Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits   Laboratory Testing Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.     

View stock analysis, news, and events for Ekf Diagnostics Holdings Plc